GlassScriptPhysician profile
James S Grisolia
NPI 1336102359
$10,392.99
in general payments reported to CMS, 2019-2025
53 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $1,225 · 2021: $2,241 · 2022: $1,496 · 2023: $899 · 2024: $1,614 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,958 · Education: $62.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,958.33 |
| Education | $62.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,343.69 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,085.38 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Novartis Pharmaceuticals Corporation | $721.08 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $571.54 | 2019-2024 | Ingrezza |
| Abbvie INC. | $565.34 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $562.20 | 2019-2025 | Ultomiris, Soliris |
| Neurelis, INC. | $468.32 | 2020-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $424.53 | 2021-2024 | Zeposia |
| Emd Serono, INC. | $391.60 | 2019-2022 | |
| Eisai INC. | $389.03 | 2019-2025 | |
| Lilly USA, LLC | $312.51 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Celgene Corporation | $230.27 | 2021-2023 | Zeposia |
| Livanova USA, INC. | $225.37 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Genzyme Corporation | $219.04 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $191.55 | 2019-2025 | Rytary, Crexont |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Grisolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.